# US 2008/0306128 A1 · Preparation of Hydrochloride Salts of Tetrazole Derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306128 A1
- Document ID: US20080306128A1
- Status: Published application
- Kind: A1
- Application number: 11/658,632
- Filed: 2005-07-29
- Published: 2008-12-11
- Earliest claimed: 2004-07-29
- Assignees: Krka, Tovarna Zdravil, D.D., Novo Mesto
- Inventors: Silvo Zupancic; Matej Smrkolj; Renata Jaske
- Web page: https://patentgrep.com/patent/US20080306128A1

## CPC

- C07D 403/10: linked by a carbon chain containing aromatic rings
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to sesquihydrate hydrochloride salt of irbesartan and anhydrous hydrochloride salts of irbesartan. Irbesartan used as the starting material for the preparation of the described hydrochlorides of irbesartan can be in any form, e.g. it can be used when contained in a reaction solution, in crude form, in a filtrate containing several solvents, or in anhydrous or any solvated or hydrated form, in amorphous form or any known crystal form or in a mixture thereof.

## Claims

### Claim 1

A Sesquihydrate hydrochloride salt of irbesartan, having 2 molecules of hydrochloride and 3 molecules of water to 2 molecules of irbesartan.

### Claim 2 (depends on 1)

The Sesquihydrate hydrochloride salt of irbesartan according to claim 1, exhibiting an X-ray powder diffractogram of FIG. 1.

### Claim 3 (depends on 1)

The Sesquihydrate hydrochloride salt of irbesartan according to claim 1, exhibiting the following 2-theta values in an X-ray powder diffractogram: 6.98, 7.47, 8.24, 11.01, 12.87, 13.18, 13.97, 14.81, 14.96, 15.33, 16.30, 17.39, 17.78, 18.30, 19.06, 20.06, 21.02, 21.57, 22.12, 22.53, 22.94, 23.39, 23.59, 24.67, 26.54, 26.97, 27.52, 28.47, 28.90, and 29.43.

### Claim 4 (depends on 1)

The Sesquihydrate hydrochloride salt of irbesartan according to claim 1, exhibiting the following 2-theta values: 7.47, 8.24, 11.01, 15.33, 17.39, 22.53, 23.39, and 26.54.

### Claim 5 (depends on 1)

The Sesquihydrate hydrochloride salt of irbesartan according to claim 1, exhibiting peaks in an IR spectrum at 1760, 1639, 1513, 1323, 943, 741 cm−1.

### Claim 6 (depends on 1)

The Sesquihydrate hydrochloride salt of irbesartan according to claim 1, containing from 5.5% to 7.0%.

### Claim 7

A Hydrochloride salt of irbesartan containing from 0% to 7% of water.

### Claim 8 (depends on 7)

The hydrochloride salt of irbesartan according to claim 7 containing 1 molecule of hydrochloride to 1 molecule of irbesartan.

### Claim 9 (depends on 7)

The hydrochloride salt of irbesartan according to claim 7 containing 1 molecule of hydrochloride to 1 molecule of irbesartan in an anhydrous form.

### Claim 10 (depends on 7)

The hydrochloride salt of irbesartan according to claim 7, exhibiting an X-ray powder diffractogram of FIG. 2.

### Claim 11 (depends on 7)

The hydrochloride salt of irbesartan according to claim 7, exhibiting the following 2-theta values in an X-ray powder diffractogram: 8.16, 10.20, 10.39, 11.61, 12.38, 12.81, 13.00, 15.74, 16.23, 17.48, 18.22, 18.78, 20.40, 21.83, 22.08, 22.38, 22.71, 23.22, 23.79, 24.38, 24.69, 24.84, 25.25, 25.55, 25.79, 27.07, 28.78, and 29.03.

### Claim 12 (depends on 7)

The hydrochloride salt of irbesartan according to claim 7, exhibiting the following 2-theta values in an X-ray powder diffractogram: 10.39, 11.61, 12.38, 12.81, 15.74, 17.48, 20.40, 21.83, 22.08, 22.38, 23.22, and 25.79.

### Claim 13 (depends on 7)

The hydrochloride salt of irbesartan according to claim 7, exhibiting peaks in IR-spectrum at 1774, 1627, 1518, 1329, 1070, 756 cm−1.

### Claim 14 (depends on 7)

The hydrochloride salt of irbesartan according to claim 7 containing 1 molecule of hydrochloride to 1 molecule of irbesartan in the amorphous form.

### Claim 15 (depends on 7)

The hydrochloride salt of irbesartan according to claim 7 exhibiting an X-ray powder diffractogram of FIG. 3.

### Claim 16 (depends on 7)

The hydrochloride salt of irbesartan according to claim 7, characterized in that it has characteristic peaks in IR-spectrum at 1773, 1627, 1509, 1321, 1065, 758 cm−1.

### Claim 17

A process for the preparation of sesquihydrate hydrochloride salt of irbesartan comprising the steps of acidifying a suspension or solution of irbesartan in water with HCl to a pH-value lower than 1.2 and stirring until sesquihydrate hydrochloride of irbesartan is precipitated.

### Claim 18 (depends on 17)

The process according to claim 17, further comprising adding a compound that decreases the surface tension of water to the suspension or solution.

### Claim 19 (depends on 18)

The process according to claim 18, wherein the compound that decreases the surface tension of water is selected from the group of alcohols.

### Claim 20 (depends on 17)

The process according to claim 17, further comprising the step of drying the precipitated sesquihydrate hydrochloride salt of irbesartan in vacuum for 1 to 5 hours at a temperature between 50° C. and room temperature.

### Claim 21

A process for the preparation of anhydrous crystal form of hydrochloride salt of irbesartan, comprising the step of heating the sesquihydrate hydrochloride salt of irbesartan, first to a temperature of about 120° C. and then to a temperature from about 120° C. to about 160° C., wherein the entire heating period lasts more than 1 hour.

### Claim 22 (depends on 21)

The process according to claim 21, wherein the duration of the entire heating period is preferably more than 3 hours.

### Claim 23

A process for the preparation of anhydrous amorphous form of hydrochloride salt of irbesartan, comprising the step of heating a sesquihydrate hydrochloride salt of irbesartan to about 160° C., wherein the entire heating lasts less than 1 hour.

### Claim 24 (depends on 23)

The process according to claim 23, wherein the duration of the entire heating is less than 20 minutes.

### Claim 25

A pharmaceutical composition comprising one or more hydrochloride salts of irbesartan and pharmaceutically acceptable carriers, diluents, excipients, additives, fillers, lubricants, binders, stabilisers, solvents or solvates.

### Claim 26 (depends on 25)

The pharmaceutical composition according to claim 25 in the form of tablets, capsules, pastilles, powder, syrup, solution, suspension, ointment or dragees.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

A method of treating hypertension or cardiac weakening by administering to a person in need thereof an effective amount of a hydrochloride salt of irbesartan.
